CRISPR Therapeutics AG (CRSP) Shares Decline Despite Market Challenges

The stock price of CRISPR Therapeutics AG (NASDAQ: CRSP) has plunged by -0.66 when compared to previous closing price of 65.03, but the company has seen a -8.98% decline in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-04-03 that ZUG, Switzerland and BOSTON, April 03, 2024 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 11:45 a.m. ET.

Is It Worth Investing in CRISPR Therapeutics AG (NASDAQ: CRSP) Right Now?

The 36-month beta value for CRSP is at 1.75. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for CRSP is 79.80M, and currently, shorts hold a 18.45% of that float. The average trading volume for CRSP on April 04, 2024 was 1.92M shares.

CRSP’s Market Performance

CRSP’s stock has seen a -8.98% decrease for the week, with a -20.97% drop in the past month and a -2.21% fall in the past quarter. The volatility ratio for the week is 3.36%, and the volatility levels for the past 30 days are at 3.79% for CRISPR Therapeutics AG The simple moving average for the past 20 days is -11.99% for CRSP’s stock, with a 8.88% simple moving average for the past 200 days.

Analysts’ Opinion of CRSP

TD Cowen, on the other hand, stated in their research note that they expect to see CRSP reach a price target of $30. The rating they have provided for CRSP stocks is “Underperform” according to the report published on December 11th, 2023.

CRSP Trading at -12.32% from the 50-Day Moving Average

After a stumble in the market that brought CRSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.09% of loss for the given period.

Volatility was left at 3.79%, however, over the last 30 days, the volatility rate increased by 3.36%, as shares sank -20.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.01% lower at present.

During the last 5 trading sessions, CRSP fell by -8.98%, which changed the moving average for the period of 200-days by +9.57% in comparison to the 20-day moving average, which settled at $72.58. In addition, CRISPR Therapeutics AG saw 3.19% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CRSP starting from Kulkarni Samarth, who sale 20,000 shares at the price of $72.48 back on Mar 15 ’24. After this action, Kulkarni Samarth now owns 208,122 shares of CRISPR Therapeutics AG, valued at $1,449,628 using the latest closing price.

Prasad Raju, the Chief Financial Officer of CRISPR Therapeutics AG, sale 3,524 shares at $72.69 during a trade that took place back on Mar 15 ’24, which means that Prasad Raju is holding 6,476 shares at $256,160 based on the most recent closing price.

Stock Fundamentals for CRSP

Current profitability levels for the company are sitting at:

  • -0.6 for the present operating margin
  • 0.65 for the gross margin

The net margin for CRISPR Therapeutics AG stands at -0.42. The total capital return value is set at -0.1. Equity return is now at value -8.17, with -6.87 for asset returns.

Based on CRISPR Therapeutics AG (CRSP), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -1.09. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is 12.51.

Currently, EBITDA for the company is -202.7 million with net debt to EBITDA at 0.71. When we switch over and look at the enterprise to sales, we see a ratio of 14.29. The receivables turnover for the company is 1.85for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.54.


In conclusion, CRISPR Therapeutics AG (CRSP) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts